NO20110169A1 - Probiotiske produkter for barn - Google Patents

Probiotiske produkter for barn Download PDF

Info

Publication number: NO20110169A1
Authority: NO; Norway
Prior art keywords: longum; infants; infant; breast milk; inflammation
Prior art date: 2008-09-19

Application number

NO20110169A

Other languages

English (en)

Norwegian (no)

Inventor

William Michael Russell

Michael Ceddia

Original Assignee

Mead Johnson Nutrition Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-09-19

Filing date

2011-02-01

Publication date

2011-03-30

2011-02-01 Application filed by Mead Johnson Nutrition Co filed Critical Mead Johnson Nutrition Co

2011-03-30 Publication of NO20110169A1 publication Critical patent/NO20110169A1/no

Links

239000006041 probiotic Substances 0.000 title claims description 30
235000018291 probiotics Nutrition 0.000 title claims description 30
230000000529 probiotic effect Effects 0.000 title claims description 19
241001608472 Bifidobacterium longum Species 0.000 claims abstract description 75
235000020256 human milk Nutrition 0.000 claims abstract description 25
210000004251 human milk Anatomy 0.000 claims abstract description 25
108090000623 proteins and genes Proteins 0.000 claims abstract description 19
235000013305 food Nutrition 0.000 claims abstract description 18
102000004169 proteins and genes Human genes 0.000 claims abstract description 15
150000001720 carbohydrates Chemical class 0.000 claims abstract description 8
206010061218 Inflammation Diseases 0.000 claims description 29
230000004054 inflammatory process Effects 0.000 claims description 29
235000013350 formula milk Nutrition 0.000 claims description 27
238000000034 method Methods 0.000 claims description 14
230000009467 reduction Effects 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
201000010099 disease Diseases 0.000 claims description 10
235000013406 prebiotics Nutrition 0.000 claims description 10
230000002265 prevention Effects 0.000 claims description 8
229920001542 oligosaccharide Polymers 0.000 claims description 6
206010012735 Diarrhoea Diseases 0.000 claims description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
235000010469 Glycine max Nutrition 0.000 claims description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 4
208000006673 asthma Diseases 0.000 claims description 4
239000008101 lactose Substances 0.000 claims description 4
150000002482 oligosaccharides Chemical class 0.000 claims description 3
244000068988 Glycine max Species 0.000 claims description 2
206010020751 Hypersensitivity Diseases 0.000 claims description 2
229920001202 Inulin Polymers 0.000 claims description 2
229920001100 Polydextrose Polymers 0.000 claims description 2
206010057190 Respiratory tract infections Diseases 0.000 claims description 2
230000007815 allergy Effects 0.000 claims description 2
HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
229940107187 fructooligosaccharide Drugs 0.000 claims description 2
235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
229940029339 inulin Drugs 0.000 claims description 2
DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 2
229960000511 lactulose Drugs 0.000 claims description 2
PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 2
239000001259 polydextrose Substances 0.000 claims description 2
235000013856 polydextrose Nutrition 0.000 claims description 2
229940035035 polydextrose Drugs 0.000 claims description 2
206010033078 Otitis media Diseases 0.000 claims 1
239000000203 mixture Substances 0.000 description 58
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 54
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 50
235000020669 docosahexaenoic acid Nutrition 0.000 description 28
229940090949 docosahexaenoic acid Drugs 0.000 description 27
235000021342 arachidonic acid Nutrition 0.000 description 25
229940114079 arachidonic acid Drugs 0.000 description 25
210000004027 cell Anatomy 0.000 description 25
238000009472 formulation Methods 0.000 description 24
241000699670 Mus sp. Species 0.000 description 23
241000186000 Bifidobacterium Species 0.000 description 19
239000000047 product Substances 0.000 description 18
230000037396 body weight Effects 0.000 description 16
102000004127 Cytokines Human genes 0.000 description 15
108090000695 Cytokines Proteins 0.000 description 15
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 15
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 15
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 15
210000001035 gastrointestinal tract Anatomy 0.000 description 15
241000894006 Bacteria Species 0.000 description 14
108091023242 Internal transcribed spacer Proteins 0.000 description 12
108010058846 Ovalbumin Proteins 0.000 description 12
229940092253 ovalbumin Drugs 0.000 description 12
235000018102 proteins Nutrition 0.000 description 12
102000003814 Interleukin-10 Human genes 0.000 description 10
108090000174 Interleukin-10 Proteins 0.000 description 10
239000003921 oil Substances 0.000 description 10
235000019198 oils Nutrition 0.000 description 10
108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
230000000694 effects Effects 0.000 description 9
235000016709 nutrition Nutrition 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
108020004414 DNA Proteins 0.000 description 8
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 8
SBHCLVQMTBWHCD-UHFFFAOYSA-N icosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC(O)=O SBHCLVQMTBWHCD-UHFFFAOYSA-N 0.000 description 8
239000000902 placebo Substances 0.000 description 8
229940068196 placebo Drugs 0.000 description 8
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
102000004889 Interleukin-6 Human genes 0.000 description 7
108090001005 Interleukin-6 Proteins 0.000 description 7
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
230000001580 bacterial effect Effects 0.000 description 7
239000002609 medium Substances 0.000 description 7
210000003289 regulatory T cell Anatomy 0.000 description 7
229920001817 Agar Polymers 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
108091028043 Nucleic acid sequence Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000000968 intestinal effect Effects 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
208000018773 low birth weight Diseases 0.000 description 6
231100000533 low birth weight Toxicity 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
235000002639 sodium chloride Nutrition 0.000 description 6
210000004988 splenocyte Anatomy 0.000 description 6
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 5
102100037850 Interferon gamma Human genes 0.000 description 5
108010074328 Interferon-gamma Proteins 0.000 description 5
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
239000008272 agar Substances 0.000 description 5
230000003115 biocidal effect Effects 0.000 description 5
235000014633 carbohydrates Nutrition 0.000 description 5
-1 encapsulations Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
229910052500 inorganic mineral Inorganic materials 0.000 description 5
244000005700 microbiome Species 0.000 description 5
235000013336 milk Nutrition 0.000 description 5
239000008267 milk Substances 0.000 description 5
210000004080 milk Anatomy 0.000 description 5
235000010755 mineral Nutrition 0.000 description 5
239000011707 mineral Substances 0.000 description 5
210000001616 monocyte Anatomy 0.000 description 5
230000002028 premature Effects 0.000 description 5
230000000770 proinflammatory effect Effects 0.000 description 5
230000004043 responsiveness Effects 0.000 description 5
230000028327 secretion Effects 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
238000003860 storage Methods 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
241000917009 Lactobacillus rhamnosus GG Species 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
150000001413 amino acids Chemical group 0.000 description 4
229940009291 bifidobacterium longum Drugs 0.000 description 4
210000000941 bile Anatomy 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 4
238000010586 diagram Methods 0.000 description 4
235000015872 dietary supplement Nutrition 0.000 description 4
235000019197 fats Nutrition 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
239000012530 fluid Substances 0.000 description 4
229910052742 iron Inorganic materials 0.000 description 4
229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 4
235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 4
239000002773 nucleotide Substances 0.000 description 4
230000005855 radiation Effects 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
229940088594 vitamin Drugs 0.000 description 4
229930003231 vitamin Natural products 0.000 description 4
235000013343 vitamin Nutrition 0.000 description 4
239000011782 vitamin Substances 0.000 description 4
108700013048 CCL2 Proteins 0.000 description 3
102000000018 Chemokine CCL2 Human genes 0.000 description 3
241000193163 Clostridioides difficile Species 0.000 description 3
229930091371 Fructose Natural products 0.000 description 3
239000005715 Fructose Substances 0.000 description 3
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241001529936 Murinae Species 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
230000000845 anti-microbial effect Effects 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
230000008859 change Effects 0.000 description 3
230000016396 cytokine production Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
239000008103 glucose Substances 0.000 description 3
150000004676 glycans Chemical class 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 3
229960002329 methacholine Drugs 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
229960003512 nicotinic acid Drugs 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
230000035935 pregnancy Effects 0.000 description 3
229940100486 rice starch Drugs 0.000 description 3
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 3
229960001225 rifampicin Drugs 0.000 description 3
239000007787 solid Substances 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
210000002784 stomach Anatomy 0.000 description 3
239000013589 supplement Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000011282 treatment Methods 0.000 description 3
QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
238000011725 BALB/c mouse Methods 0.000 description 2
102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
241000589875 Campylobacter jejuni Species 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
102000029816 Collagenase Human genes 0.000 description 2
108060005980 Collagenase Proteins 0.000 description 2
AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
108010000912 Egg Proteins Proteins 0.000 description 2
102000002322 Egg Proteins Human genes 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241001646719 Escherichia coli O157:H7 Species 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 2
ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 2
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
235000019486 Sunflower oil Nutrition 0.000 description 2
230000006052 T cell proliferation Effects 0.000 description 2
229930003316 Vitamin D Natural products 0.000 description 2
240000008042 Zea mays Species 0.000 description 2
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
235000002017 Zea mays subsp mays Nutrition 0.000 description 2
208000037883 airway inflammation Diseases 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
239000002585 base Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
235000013361 beverage Nutrition 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229940041514 candida albicans extract Drugs 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000007969 cellular immunity Effects 0.000 description 2
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
229960002424 collagenase Drugs 0.000 description 2
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
235000005822 corn Nutrition 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
229960002104 cyanocobalamin Drugs 0.000 description 2
235000000639 cyanocobalamin Nutrition 0.000 description 2
239000011666 cyanocobalamin Substances 0.000 description 2
230000001351 cycling effect Effects 0.000 description 2
ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
235000013345 egg yolk Nutrition 0.000 description 2
210000002969 egg yolk Anatomy 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
235000013861 fat-free Nutrition 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
235000021323 fish oil Nutrition 0.000 description 2
235000013312 flour Nutrition 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
229930182830 galactose Natural products 0.000 description 2
239000011521 glass Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000000395 magnesium oxide Substances 0.000 description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
239000011733 molybdenum Substances 0.000 description 2
229910052750 molybdenum Inorganic materials 0.000 description 2
235000016768 molybdenum Nutrition 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
244000052769 pathogen Species 0.000 description 2
239000008188 pellet Substances 0.000 description 2
235000019175 phylloquinone Nutrition 0.000 description 2
239000011772 phylloquinone Substances 0.000 description 2
MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
229960001898 phytomenadione Drugs 0.000 description 2
235000007715 potassium iodide Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
230000004044 response Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
229960002477 riboflavin Drugs 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000002600 sunflower oil Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000012546 transfer Methods 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
239000013598 vector Substances 0.000 description 2
238000011179 visual inspection Methods 0.000 description 2
235000019166 vitamin D Nutrition 0.000 description 2
239000011710 vitamin D Substances 0.000 description 2
150000003710 vitamin D derivatives Chemical class 0.000 description 2
235000005282 vitamin D3 Nutrition 0.000 description 2
239000011647 vitamin D3 Substances 0.000 description 2
229940046008 vitamin d Drugs 0.000 description 2
229940021056 vitamin d3 Drugs 0.000 description 2
229940041603 vitamin k 3 Drugs 0.000 description 2
239000012138 yeast extract Substances 0.000 description 2
DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
OAJLVMGLJZXSGX-CXGXMSGESA-L (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-methanidyloxolane-3,4-diol;cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 1-[3-[(4z,9z,14z)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8 Chemical compound [Co+3].O[C@@H]1[C@H](O)[C@@H]([CH2-])O[C@H]1N1C2=NC=NC(N)=C2N=C1.O([C@H]1[C@H]([C@H](O[C@@H]1CO)N1C2=CC(C)=C(C)C=C2N=C1)O)P([O-])(=O)OC(C)CNC(=O)CCC1(C)C(CC(N)=O)C2[N-]\C1=C(C)/C(C(C\1(C)C)CCC(N)=O)=N/C/1=C\C(C(C/1(CC(N)=O)C)CCC(N)=O)=N\C\1=C(C)/C1=NC2(C)C(C)(CC(N)=O)C1CCC(N)=O OAJLVMGLJZXSGX-CXGXMSGESA-L 0.000 description 1
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
206010059447 Allergic colitis Diseases 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241001655328 Bifidobacteriales Species 0.000 description 1
241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
206010006448 Bronchiolitis Diseases 0.000 description 1
108010076119 Caseins Proteins 0.000 description 1
GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
229910021555 Chromium Chloride Inorganic materials 0.000 description 1
241001112696 Clostridia Species 0.000 description 1
GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
206010011416 Croup infectious Diseases 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
230000008836 DNA modification Effects 0.000 description 1
230000009946 DNA mutation Effects 0.000 description 1
UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012742 Diarrhoea infectious Diseases 0.000 description 1
108010082495 Dietary Plant Proteins Proteins 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
208000004262 Food Hypersensitivity Diseases 0.000 description 1
108010052764 Fructose-6-phosphate phosphoketolase Proteins 0.000 description 1
206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
108010073032 Grain Proteins Proteins 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
102000010445 Lactoferrin Human genes 0.000 description 1
108010063045 Lactoferrin Proteins 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
108010011756 Milk Proteins Proteins 0.000 description 1
102000014171 Milk Proteins Human genes 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
229930192627 Naphthoquinone Natural products 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000002389 Pouchitis Diseases 0.000 description 1
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
235000019485 Safflower oil Nutrition 0.000 description 1
241000831652 Salinivibrio sharmensis Species 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
108010073771 Soybean Proteins Proteins 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046306 Upper respiratory tract infection Diseases 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003779 Vitamin B12 Natural products 0.000 description 1
229930003471 Vitamin B2 Natural products 0.000 description 1
229930003537 Vitamin B3 Natural products 0.000 description 1
LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
229930003448 Vitamin K Natural products 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
239000013566 allergen Substances 0.000 description 1
208000037884 allergic airway inflammation Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
235000020661 alpha-linolenic acid Nutrition 0.000 description 1
230000004075 alteration Effects 0.000 description 1
235000021120 animal protein Nutrition 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
241000385736 bacterium B Species 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000013734 beta-carotene Nutrition 0.000 description 1
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
239000011648 beta-carotene Substances 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
229960002747 betacarotene Drugs 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
235000015895 biscuits Nutrition 0.000 description 1
239000006161 blood agar Substances 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
239000001639 calcium acetate Substances 0.000 description 1
235000011092 calcium acetate Nutrition 0.000 description 1
229960005147 calcium acetate Drugs 0.000 description 1
229960002079 calcium pantothenate Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
229940068682 chewable tablet Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
229960002227 clindamycin Drugs 0.000 description 1
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
239000007399 clostridium medium Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
235000014510 cooky Nutrition 0.000 description 1
239000010949 copper Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
229940108925 copper gluconate Drugs 0.000 description 1
229910000365 copper sulfate Inorganic materials 0.000 description 1
229960000355 copper sulfate Drugs 0.000 description 1
229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
201000010549 croup Diseases 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000000254 damaging effect Effects 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001934 delay Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
208000022602 disease susceptibility Diseases 0.000 description 1
BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
229960000878 docusate sodium Drugs 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
208000001848 dysentery Diseases 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
208000010227 enterocolitis Diseases 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229960002061 ergocalciferol Drugs 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000008713 feedback mechanism Effects 0.000 description 1
239000011773 ferrous fumarate Substances 0.000 description 1
235000002332 ferrous fumarate Nutrition 0.000 description 1
229960000225 ferrous fumarate Drugs 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
235000019162 flavin adenine dinucleotide Nutrition 0.000 description 1
239000011714 flavin adenine dinucleotide Substances 0.000 description 1
VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
229940013640 flavin mononucleotide Drugs 0.000 description 1
239000011768 flavin mononucleotide Substances 0.000 description 1
FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
235000020932 food allergy Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
235000015203 fruit juice Nutrition 0.000 description 1
229940098330 gamma linoleic acid Drugs 0.000 description 1
VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007897 gelcap Substances 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
231100000024 genotoxic Toxicity 0.000 description 1
230000001738 genotoxic effect Effects 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
244000005709 gut microbiome Species 0.000 description 1
230000036541 health Effects 0.000 description 1
230000003862 health status Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000007366 host health Effects 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
208000022760 infectious otitis media Diseases 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000031261 interleukin-10 production Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000004207 intestinal integrity Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
230000003870 intestinal permeability Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
WBJZTOZJJYAKHQ-UHFFFAOYSA-K iron(3+) phosphate Chemical compound [Fe+3].[O-]P([O-])([O-])=O WBJZTOZJJYAKHQ-UHFFFAOYSA-K 0.000 description 1
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
229910000399 iron(III) phosphate Inorganic materials 0.000 description 1
208000002551 irritable bowel syndrome Diseases 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
235000021242 lactoferrin Nutrition 0.000 description 1
229940078795 lactoferrin Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229960004232 linoleic acid Drugs 0.000 description 1
229960004488 linolenic acid Drugs 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000014666 liquid concentrate Nutrition 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
230000035800 maturation Effects 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
239000000155 melt Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
235000007672 methylcobalamin Nutrition 0.000 description 1
239000011585 methylcobalamin Substances 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
235000021243 milk fat Nutrition 0.000 description 1
235000021239 milk protein Nutrition 0.000 description 1
229960003128 mupirocin Drugs 0.000 description 1
229930187697 mupirocin Natural products 0.000 description 1
DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229950006238 nadide Drugs 0.000 description 1
150000002791 naphthoquinones Chemical class 0.000 description 1
230000004719 natural immunity Effects 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000031990 negative regulation of inflammatory response Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229960003966 nicotinamide Drugs 0.000 description 1
235000005152 nicotinamide Nutrition 0.000 description 1
239000011570 nicotinamide Substances 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
235000015816 nutrient absorption Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000003346 palm kernel oil Substances 0.000 description 1
235000019865 palm kernel oil Nutrition 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
229940055726 pantothenic acid Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Substances [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
229960004839 potassium iodide Drugs 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
108010021380 pregestimil Proteins 0.000 description 1
231100000586 procarcinogen Toxicity 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000000722 protumoral effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
239000011764 pyridoxine hydrochloride Substances 0.000 description 1
229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
235000020945 retinal Nutrition 0.000 description 1
239000011604 retinal Substances 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
235000020944 retinol Nutrition 0.000 description 1
239000011607 retinol Substances 0.000 description 1
229960003471 retinol Drugs 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
235000019192 riboflavin Nutrition 0.000 description 1
239000002151 riboflavin Substances 0.000 description 1
235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
235000005713 safflower oil Nutrition 0.000 description 1
239000003813 safflower oil Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
239000006152 selective media Substances 0.000 description 1
239000011669 selenium Substances 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
235000011649 selenium Nutrition 0.000 description 1
229940091258 selenium supplement Drugs 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
239000011684 sodium molybdate Substances 0.000 description 1
235000015393 sodium molybdate Nutrition 0.000 description 1
TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
239000011655 sodium selenate Substances 0.000 description 1
235000018716 sodium selenate Nutrition 0.000 description 1
229960001881 sodium selenate Drugs 0.000 description 1
239000011781 sodium selenite Substances 0.000 description 1
235000015921 sodium selenite Nutrition 0.000 description 1
229960001471 sodium selenite Drugs 0.000 description 1
229940001941 soy protein Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
238000003239 susceptibility assay Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960003495 thiamine Drugs 0.000 description 1
239000011721 thiamine Substances 0.000 description 1
235000019157 thiamine Nutrition 0.000 description 1
KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
229960004860 thiamine mononitrate Drugs 0.000 description 1
235000019191 thiamine mononitrate Nutrition 0.000 description 1
239000011748 thiamine mononitrate Substances 0.000 description 1
UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
229960002363 thiamine pyrophosphate Drugs 0.000 description 1
235000008170 thiamine pyrophosphate Nutrition 0.000 description 1
239000011678 thiamine pyrophosphate Substances 0.000 description 1
YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229940042585 tocopherol acetate Drugs 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
239000006150 trypticase soy agar Substances 0.000 description 1
108010050327 trypticase-soy broth Proteins 0.000 description 1
239000007195 tryptone soya broth Substances 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
235000019163 vitamin B12 Nutrition 0.000 description 1
239000011715 vitamin B12 Substances 0.000 description 1
235000019164 vitamin B2 Nutrition 0.000 description 1
239000011716 vitamin B2 Substances 0.000 description 1
235000019160 vitamin B3 Nutrition 0.000 description 1
239000011708 vitamin B3 Substances 0.000 description 1
235000019158 vitamin B6 Nutrition 0.000 description 1
239000011726 vitamin B6 Substances 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
235000001892 vitamin D2 Nutrition 0.000 description 1
239000011653 vitamin D2 Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
235000019168 vitamin K Nutrition 0.000 description 1
239000011712 vitamin K Substances 0.000 description 1
150000003721 vitamin K derivatives Chemical class 0.000 description 1
235000019143 vitamin K2 Nutrition 0.000 description 1
239000011728 vitamin K2 Substances 0.000 description 1
235000012711 vitamin K3 Nutrition 0.000 description 1
239000011652 vitamin K3 Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
229940011671 vitamin b6 Drugs 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
229940046010 vitamin k Drugs 0.000 description 1
235000021119 whey protein Nutrition 0.000 description 1
239000002676 xenobiotic agent Substances 0.000 description 1
230000002034 xenobiotic effect Effects 0.000 description 1
235000013618 yogurt Nutrition 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
229910000368 zinc sulfate Inorganic materials 0.000 description 1
229960001763 zinc sulfate Drugs 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Mycology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Polymers & Plastics (AREA)
Food Science & Technology (AREA)
Nutrition Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Pediatric Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Dairy Products (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20110169A 2008-09-19 2011-02-01 Probiotiske produkter for barn NO20110169A1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US12/284,230 US8137718B2 (en)	2008-09-19	2008-09-19	Probiotic infant products
PCT/US2009/057426 WO2010033768A1 (fr)	2008-09-19	2009-09-18	Probiotiques pour bébés

Publications (1)

Publication Number	Publication Date
NO20110169A1 true NO20110169A1 (no)	2011-03-30

Family

ID=42037894

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20110169A NO20110169A1 (no)	2008-09-19	2011-02-01	Probiotiske produkter for barn

Country Status (15)

Country	Link
US (1)	US8137718B2 (fr)
EP (1)	EP2323494B8 (fr)
CN (1)	CN102159085B (fr)
BR (1)	BRPI0918641A8 (fr)
CA (1)	CA2737655A1 (fr)
CO (2)	CO6351696A2 (fr)
CZ (1)	CZ2011140A3 (fr)
ES (1)	ES2398188T3 (fr)
MX (1)	MX2011002239A (fr)
NO (1)	NO20110169A1 (fr)
PE (1)	PE20110932A1 (fr)
PL (1)	PL2323494T3 (fr)
RU (1)	RU2011115226A (fr)
TW (1)	TW201026239A (fr)
WO (1)	WO2010033768A1 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008117267A2 (fr) *	2007-03-28	2008-10-02	Alimentary Health Limited	Souches de bifidobacterium probiotiques
US8498729B2 (en)	2008-08-29	2013-07-30	Smp Logic Systems Llc	Manufacturing execution system for use in manufacturing baby formula
WO2010063601A1 (fr) *	2008-12-05	2010-06-10	Nestec S.A.	Compositions pour utilisation chez des nourrissons à faible poids à la naissance
RU2556124C2 (ru) *	2009-05-11	2015-07-10	Нестек С.А.	Lactobacillus johnsonii La1 NСС533 (CNCM 1-1225) И ИММУННЫЕ НАРУШЕНИЯ
ES2565407T3 (es) *	2010-11-05	2016-04-04	Nestec S.A.	Procedimiento para la preparación de un producto alimenticio para animales de compañía, el cual contiene microorganismos probióticos
EP2455092A1 (fr)	2010-11-11	2012-05-23	Nestec S.A.	Protection de micro-organismes probiotiques sans réplication contre les infections des voies respiratoires supérieures
EP2452575A1 (fr) *	2010-11-15	2012-05-16	Nestec S.A.	Analyse de formule nutritionnelle personnalisée en fonction de l'âge avec des probiotiques
US20120135103A1 (en) *	2010-11-30	2012-05-31	Mead Johnson Nutrition Company	Staged Infant Feeding Regimen To Promote Healthy Development And Growth
US9375028B2 (en)	2010-12-09	2016-06-28	Mead Johnson Nutrition Company	Compositions and methods for nutrient delivery
US20120171164A1 (en) *	2010-12-29	2012-07-05	Anja Wittke	Use of nutritional compositions including lactoferrin in supporting resistance to viral respiratory tract infections
EP2658559A1 (fr) *	2010-12-29	2013-11-06	Nestec S.A.	Fibre et probiotiques pour la réduction des symptômes intestinaux liés au stress
ITMI20110791A1 (it)	2011-05-09	2012-11-10	Probiotical Spa	Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110793A1 (it) *	2011-05-09	2012-11-10	Probiotical Spa	Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITMI20110792A1 (it)	2011-05-09	2012-11-10	Probiotical Spa	Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
GB201112091D0 (en)	2011-07-14	2011-08-31	Gt Biolog Ltd	Bacterial strains isolated from pigs
ITMI20111718A1 (it)	2011-09-23	2013-03-24	Probiotical Spa	Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
TR201109721A2 (tr)	2011-09-30	2012-03-21	Spi̇l Teknoloji̇ Bi̇li̇şi̇m İnternet Ve Web Tasarim Hi̇zmetleri̇ Özel Eği̇ti̇m Öğreti̇m Kurumlari Ve Danişmanlik Elektri̇k Elektroni̇k İnşaat Gida İmalat İthalat İhracat San. Ve Ti̇c. Ltd. Şti̇.	Zeytinli bebek ek besini.
GB201117313D0 (en)	2011-10-07	2011-11-16	Gt Biolog Ltd	Bacterium for use in medicine
US9474298B2 (en) *	2011-10-11	2016-10-25	Mead Johnson Nutrition Company	Partially hydrolyzed casein-whey nutritional compositions for reducing the onset of allergies
US20130095204A1 (en) *	2011-10-14	2013-04-18	Zeina Jouni	Nutritional phytonutrient compositions
US20130251829A1 (en) *	2012-03-23	2013-09-26	Mead Johnson Nutrition Company	Probiotic derived non-viable material for infection prevention and treatment
US20140242216A1 (en) *	2013-02-24	2014-08-28	Mead Johnson Nutrition Company	Amino Acid And Protein Hydrolysate Based Formulas With A Stable Emulsion System
US20140271979A1 (en) *	2013-03-15	2014-09-18	Mead Johnson Nutrition Company	Anti-regurgitation nutritional composition
GB201306536D0 (en)	2013-04-10	2013-05-22	Gt Biolog Ltd	Polypeptide and immune modulation
ITMI20130793A1 (it)	2013-05-14	2014-11-15	Probiotical Spa	Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
WO2014200334A1 (fr)	2013-06-14	2014-12-18	N.V. Nutricia	Composition synbiotique pour le traitement d'infections chez des patients allergiques
CN103820357A (zh) *	2013-12-30	2014-05-28	上海交大昂立股份有限公司	一株长双歧杆菌及其防治食物过敏的功能
EP3128859A1 (fr)	2014-03-26	2017-02-15	Abbott Laboratories	Poudre de complément nutritionnel
US20150305359A1 (en) *	2014-04-24	2015-10-29	Mead Johnson Nutrition Company	Nutritional compositions directed to subjects having cow's milk protein allergies
US20150305384A1 (en) *	2014-04-25	2015-10-29	Mead Johnson Nutrition Company	Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
US20150305385A1 (en) *	2014-04-25	2015-10-29	Mead Johnson Nutrition Company	Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
HUE035569T2 (en)	2014-12-23	2018-05-28	4D Pharma Res Ltd	Bacteroides thetaiotaomicron strain and its use in reducing inflammation
KR20170091157A (ko)	2014-12-23	2017-08-08	4디 파마 리서치 리미티드	피린 폴리펩티드 및 면역 조정
ES2753779T3 (es)	2015-06-15	2020-04-14	4D Pharma Res Ltd	Blautia stercosis y wexlerae para la utilización en el tratamiento de enfermedades inflamatorias y autoinmunes
MA41060B1 (fr)	2015-06-15	2019-11-29	4D Pharma Res Ltd	Compositions comprenant des souches bactériennes
HUE045413T2 (hu)	2015-06-15	2019-12-30	4D Pharma Res Ltd	Baktériumtörzseket tartalmazó készítmények
LT3360559T (lt)	2015-06-15	2019-12-27	4D Pharma Research Limited	Kompozicijos, apimančios bakterijų kamienus
MA41010B1 (fr)	2015-06-15	2020-01-31	4D Pharma Res Ltd	Compositions comprenant des souches bactériennes
CN105112333A (zh) *	2015-08-31	2015-12-02	江南大学	一种具有良好肠道定殖能力的长双歧杆菌及筛选方法和应用
GB201520497D0 (en)	2015-11-20	2016-01-06	4D Pharma Res Ltd	Compositions comprising bacterial strains
CN108513545B (zh)	2015-11-20	2020-11-03	4D制药研究有限公司	包含细菌菌株的组合物
GB201520631D0 (en)	2015-11-23	2016-01-06	4D Pharma Res Ltd	Compositions comprising bacterial strains
GB201520638D0 (en)	2015-11-23	2016-01-06	4D Pharma Res Ltd	Compositions comprising bacterial strains
US10751308B2 (en) *	2016-01-26	2020-08-25	Societe Des Produits Nestle S.A.	Composition for preventing or reducing transepidermal water loss
US10912323B2 (en)	2016-02-29	2021-02-09	Abbott Laboratories	Nutritional supplement powder
SG11201807195VA (en)	2016-03-04	2018-09-27	4D Pharma Plc	Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en)	2016-07-13	2016-08-24	4D Pharma Plc	Compositions comprising bacterial strains
MA45334A (fr)	2016-03-24	2019-01-30	Probiotical Spa	Composition bactérienne d'acide lactique pour le traitement d'infections vaginales bactériennes par gardnerella vaginalis et, éventuellement, d'infections fongiques concurrentes
TW201821093A (zh)	2016-07-13	2018-06-16	英商４Ｄ製藥有限公司	包含細菌菌株之組合物
GB201621123D0 (en)	2016-12-12	2017-01-25	4D Pharma Plc	Compositions comprising bacterial strains
HUE054164T2 (hu)	2017-05-22	2021-08-30	4D Pharma Res Ltd	Baktériumtörzseket tartalmazó készítmények
JP6978514B2 (ja)	2017-05-24	2021-12-08	フォーディーファーマリサーチリミテッド4D Pharma Research Limited	細菌株を含む組成物
SMT202000695T1 (it)	2017-06-14	2021-01-05	4D Pharma Res Limited	Composizioni comprendenti ceppi batterici
JP2020523326A (ja)	2017-06-14	2020-08-06	フォーディーファーマリサーチリミテッド４ＤＰｈａｒｍａＲｅｓｅａｒｃｈＬｉｍｉｔｅｄ	細菌株を含む組成物
ES2855701T3 (es)	2017-06-14	2021-09-24	4D Pharma Res Ltd	Composiciones que comprenden cepas bacterianas
WO2019090093A1 (fr) *	2017-11-03	2019-05-09	Advanced Bionutrition Corp.	Composition contenant des micro-organismes viables et ses procédés de préparation
FR3078609B1 (fr) *	2018-03-08	2020-02-21	Abcd Nutrition	Composition pour diminuer la sensibilite au gluten
FR3078610B1 (fr) *	2018-03-08	2020-02-21	Abcd Nutrition	Composition de probiotiques particuliers et utilisation pour diminuer les symptomes inflammatoires digestifs
CN118475253A (zh) *	2021-12-20	2024-08-09	雀巢产品有限公司	分泌型IgA-生物制剂复合物及其用途
CN114276961A (zh) *	2021-12-30	2022-04-05	光明乳业股份有限公司	一种长双歧杆菌婴儿亚种ccfm1192菌株、发酵剂及其制备方法与应用
CN120000694A (zh) *	2025-02-24	2025-05-16	合生元（广州）健康产品有限公司	一种用于缓解呼吸道不适的组合物及其应用和产品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5843698A (en)	1997-04-30	1998-12-01	Universal Ventures	Deleteriously affecting members of a target species by exposure to a component of symbiont or food source of an adjoiner species that is symbiotic with the target species
US5902743A (en)	1998-03-20	1999-05-11	Wisconsin Alumni Research Foundation	Probiotic bifidobacterium strain
US6074815A (en)	1999-03-08	2000-06-13	Universal Ventures	Selection of test species for testing to identify components thereof that deleteriously affect a target species member
US6150127A (en)	1999-11-30	2000-11-21	Universal Ventures	Causing a desirable change in a behavior pattern
US7179460B2 (en) *	2002-12-05	2007-02-20	Danisco A/S	Bacterial composition and its use
CA2532489C (fr)	2003-06-23	2012-12-11	Nestec S.A.	Preparation pour nourrissons et jeunes enfants
WO2005115341A2 (fr) *	2004-05-27	2005-12-08	Advanced Bionutrition Corporation	Microparticules pour administration orale
WO2008117267A2 (fr)	2007-03-28	2008-10-02	Alimentary Health Limited	Souches de bifidobacterium probiotiques

2008
- 2008-09-19 US US12/284,230 patent/US8137718B2/en not_active Expired - Fee Related
2009
- 2009-09-18 WO PCT/US2009/057426 patent/WO2010033768A1/fr not_active Ceased
- 2009-09-18 CA CA2737655A patent/CA2737655A1/fr not_active Abandoned
- 2009-09-18 TW TW098131600A patent/TW201026239A/zh unknown
- 2009-09-18 BR BRPI0918641A patent/BRPI0918641A8/pt not_active IP Right Cessation
- 2009-09-18 MX MX2011002239A patent/MX2011002239A/es active IP Right Grant
- 2009-09-18 PL PL09815242T patent/PL2323494T3/pl unknown
- 2009-09-18 EP EP09815242A patent/EP2323494B8/fr not_active Not-in-force
- 2009-09-18 CN CN2009801361470A patent/CN102159085B/zh not_active Expired - Fee Related
- 2009-09-18 ES ES09815242T patent/ES2398188T3/es active Active
- 2009-09-18 CZ CZ20110140A patent/CZ2011140A3/cs unknown
- 2009-09-18 RU RU2011115226/10A patent/RU2011115226A/ru unknown
- 2009-09-18 PE PE2011000452A patent/PE20110932A1/es not_active Application Discontinuation
2011
- 2011-02-01 NO NO20110169A patent/NO20110169A1/no not_active Application Discontinuation
- 2011-02-28 CO CO11024076A patent/CO6351696A2/es active IP Right Grant
- 2011-02-28 CO CO11024074A patent/CO6351695A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN102159085B (zh)	2013-10-02
CO6351695A2 (es)	2011-12-20
CO6351696A2 (es)	2011-12-20
CZ2011140A3 (cs)	2011-09-07
WO2010033768A1 (fr)	2010-03-25
US8137718B2 (en)	2012-03-20
PE20110932A1 (es)	2012-01-29
TW201026239A (en)	2010-07-16
EP2323494A4 (fr)	2011-11-02
CN102159085A (zh)	2011-08-17
HK1160729A1 (en)	2012-08-17
RU2011115226A (ru)	2012-10-27
EP2323494B8 (fr)	2012-12-26
EP2323494B1 (fr)	2012-10-24
BRPI0918641A8 (pt)	2016-04-12
CA2737655A1 (fr)	2010-03-25
EP2323494A1 (fr)	2011-05-25
BRPI0918641A2 (pt)	2015-08-25
ES2398188T3 (es)	2013-03-14
PL2323494T3 (pl)	2013-03-29
MX2011002239A (es)	2011-04-05
US20100074871A1 (en)	2010-03-25

Publication	Publication Date	Title
EP2323494B1 (fr)	2012-10-24	Probiotiques pour bébés
EP2323493B1 (fr)	2012-10-24	Probiotiques pour bébés
NL2004201C2 (en)	2011-08-08	Use of sialyl oligosaccharides to modulate the immune system.
US11998577B2 (en)	2024-06-04	Methods for increasing growth of beneficial bacteria in the gastrointestinal tract
Isolauri et al.	2008	Modulation of the maturing gut barrier and microbiota: a novel target in allergic disease
CA2822219C (fr)	2020-12-29	Methodes visant a diminuer la frequence de l'enterocolite necrosante chez les nourrissons, les jeunes enfants ou les enfants a l'aide d'oligosaccharides du lait humain
CA2822500C (fr)	2022-07-26	Oligosaccharides de lait humain pour favoriser la croissance de bacteries benefiques
US20210139842A1 (en)	2021-05-13	Novel bifidobacterium bacteria and composition including novel bifidobacterium bacteria
SG191798A1 (en)	2013-08-30	Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
CN117377397A (zh)	2024-01-09	合生素组合物
JP6998193B2 (ja)	2022-02-10	新規ビフィドバクテリウム属細菌及び当該細菌を含む組成物
WO2024101341A1 (fr)	2024-05-16	Composition pour nouveau-nés ou nourrissons
WO2022200337A1 (fr)	2022-09-29	Oligosaccharides de lait humain
JP2023062563A (ja)	2023-05-08	栄養組成物
HK1160729B (en)	2014-06-20	Probiotic infant products
HK1160730B (en)	2013-12-06	Probiotic infant products
HK1158025B (en)	2013-03-22	Probiotic infant products
WO2025182553A1 (fr)	2025-09-04	Composition pour nouveau-nés ou nourrissons
JP2023530672A (ja)	2023-07-19	胃腸バリアを改善するための３－ヒドロキシ酪酸を含む栄養組成物

Legal Events

Date	Code	Title	Description
2013-04-22	FC2A	Withdrawal, rejection or dismissal of laid open patent application